# DESCRIPTION

## FIELD OF THE INVENTION

- introduce ectodermal dysplasias

## BACKGROUND OF THE INVENTION

- describe ectodermal dysplasias
- discuss X-linked hypohidrotic ectodermal dysplasia
- motivate need for treatment
- summarize prior art approaches
- highlight limitations of prior art

## SUMMARY OF THE INVENTION

- outline method for producing agonist anti-EDAR monoclonal antibodies
- describe isolated agonist anti-EDAR monoclonal antibodies and their uses

## DETAILED DESCRIPTION OF THE INVENTION

- define key terms
- describe protein and peptide definitions
- explain antibody and antigen definitions
- outline receptor and epitope definitions
- detail monoclonal antibody and fragment definitions
- describe method for producing agonist anti-EDAR monoclonal antibodies
- specify preferred EDAR antigen forms
- describe EDAR antigen
- outline antibody production process
- detail binding assays
- describe purification methods
- illustrate preferred embodiment
- discuss unanticipated results
- define specific binding and affinity constants
- classify amino acid residues
- describe antibody fragments and modifications
- specify antibody heavy and light chain regions
- define isotype and isotype switching
- provide isolated agonist anti-EDAR monoclonal antibodies
- discuss sequence identity and variants
- describe antibody modifications
- describe pegylation
- describe deamidation and isoaspartic acid effects
- describe antibody selection criteria
- describe nucleic acid molecules encoding antibodies
- describe chimeric and humanized antibodies
- describe expression vectors and host cells
- describe pharmaceutical compositions and transgenic animals
- describe pharmaceutical composition
- list physiologically acceptable carriers
- discuss adjuvants and antioxidants
- describe routes of administration
- discuss dosage regimens
- describe therapeutic effects
- outline use of medicament
- describe antibody properties
- outline therapeutic applications
- detail pharmaceutical compositions
- describe agonist anti-EDAR antibodies
- motivate veterinary applications
- describe screening for complementary variable domain region sequences
- specify antibody, antibody fragment, or antigen binding portion or fragment thereof
- describe substitutable positions
- identify novel antigenic portion of human and mouse EDAR
- describe properties of isolated monoclonal antibody or isolated monoclonal antibody fragment or antigen binding portion or fragment thereof
- define antibody fragments
- describe chimeric antibodies
- describe fusion proteins
- define antigenic determinants
- describe conjugation of antibodies with ligands/tags
- list exemplary ligands
- describe labeling/tagging of antibodies
- describe linkers and linking methods
- define chemical moieties
- define terms
- describe objects of invention
- provide pharmaceutical composition
- describe use of medicament
- provide examples and references

## EXAMPLES

### Example 1

- prepare EDAR-Fc expression vector
- generate stably expressing EDAR-Fc 293 cells
- purify EDAR-Fc recombinant fusion protein
- immunize EDAR-deficient mice
- detect anti-EDAR antibodies in serum
- generate hybridoma cells
- produce and purify monoclonal antibodies

### Example 2

- bind anti-EDAR antibodies to human and mouse EDAR

### Example 3

- map region on EDAR recognized by anti-EDAR mAb

### Example 4

- evaluate competition between APO200 and anti-EDAR mAb for binding to EDAR

### Example 5

- test polyclonal anti-EDAR antibodies for agonist activity

### Example 6

- determine half-life of anti-EDAR mAb

### Example 7

- determine therapeutic dose of anti-EDAR mAb

### Example 8

- correct Tabby phenotype following injection of anti-EDAR mAb

### Example 9

- examine dentition of Tabby mice treated with anti-EDAR mAb
- compare teeth of treated Tabby mice and wild type mice
- show similarity in teeth development

